Show simple item record

dc.contributor.authorCatovsky, D
dc.date.accessioned2018-07-13T10:16:18Z
dc.date.issued2011-02
dc.identifierhttp://publications.icr.ac.uk/10431/
dc.identifier.citationBLOOD, 2011, 117 (5), pp. 1516 - 1521
dc.identifier.issn0006-4971
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2055
dc.description.abstractWe present results of a phase 3 randomized trial of autografting in chronic lymphocytic leukemia versus observation for responding patients after first-or second-line treatment. The primary objective was to demonstrate that autografting improves the 5-year event-free survival (EFS) from 30% to 50%. There were 223 enrolled patients, 72% men and 28% women, 83% after first and 17% after second-line treatment. Binet stages were progressive A 13%, B 67%, C 20%; at randomization, 59% were in complete remission, and 41% in less than complete remission. Patients were randomized between autografting (n = 112) and observation (n = 111). Median EFS was 24.4 months (range, 16.7-32 months) in the observation group and 51.2 months (39.8-62.5 months) in the autografting group; the 5-year EFS was 24% and 42%, respectively (P < .001). Accordingly, the 5-year relapse incidence was 76% versus 54% (P < .001). Median time to relapse requiring therapy or death was 40 months (25-56 months) in the observation arm and 65 months (59-71 months) after autografting (P = .002). Cox modeling confirmed that autografting significantly improved EFS (hazard ratio 0.44, 95% confidence interval 0.30-0.65; P < .001). At 5 years, the probability of OS was 85.5% and 84.3% for autografting and observation, respectively (P = .77). In chronic lymphocytic leukemia, consolidating autografting reduces the risk of progression by more than 50% but has no effect on overall survival. (Blood. 2011; 117(5):1516-1521)
dc.format.extent1516 - 1521
dc.languageeng
dc.language.isoeng
dc.publisherAMER SOC HEMATOLOGY
dc.subjectBONE-MARROW-TRANSPLANTATION; RESIDUAL DISEASE; MATCHED ANALYSIS; FLUDARABINE; CYCLOPHOSPHAMIDE; RITUXIMAB; GENE; MOBILIZATION; ALEMTUZUMAB; DIAGNOSIS
dc.titleAutologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation
dc.typeJournal Article
rioxxterms.licenseref.startdate2011-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBLOOD
pubs.issue5
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.volume117
pubs.embargo.termsNot known
dc.contributor.icrauthorCatovsky, Danielen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record